t
| TIDM | AMS |
| Share Price | 280.50p-0.53% |
| Market Cap | £615.99m |
Advanced Medical Solutions Group plc (AMS) announced on 27 October 2025 its participation in upcoming investor conferences. AMS will attend the Investec UK CEO Conference in London on 11 November 2025 and the Berenberg European Conference in Windsor on 4 December 2025, both involving one-on-one and group investor meetings.
27 October 2025
Advanced Medical Solutions Group plc
("AMS" or the "Group")
AMS to participate in upcoming investor conferences in November and December
Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), the innovative tissue healing medical device company delivering high-performing, cost-effective solutions for better patient outcomes, today announces that the Group will be participating in the following investor conferences in November and December:
· Investec UK CEO Conference, London
Date: 11 November 2025
Format: One-on-one and group investor meetings
· Berenberg European Conference, Windsor
Date: 4 December 2025
Format: One-on-one and group investor meetings
- End -
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations |
|
|
|
|
|
Optimum Strategic Communications |
Tel: +44 (0) 20 4566 8543 |
|
Mary Clark / Nick Bastin / Isabelle Abdou |
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Gary Clarence / David Anderson |
|
|
Berenberg (Joint Broker) |
Tel: +44 (0)20 3207 7800 |
|
Toby Flaux / Detlir Elezi |
|
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is an innovative tissue healing medical device company delivering high-performing, cost-effective solutions that match or surpass market leaders, clinically, technically, and commercially. From adhesives and sealants, to biosurgical devices and sutures, AMS's products offer superior usability, quality and design. AMS's strength lies in combining advanced material science with applicator device design and development, in collaboration with surgeons and Key Opinion Leaders, creating differentiated devices that improve patient outcomes without compromising quality or affordability.
AMS's scalable, resilient business model is built on disciplined execution, portfolio focus, and capital efficiency. Its diversified product and geographic mix mitigates volatility, ensuring consistent performance even when individual segments fluctuate. Following its acquisition of Peters Surgical, AMS is unlocking operational and commercial synergies, accelerating its U.S. and international expansion, and increasing the percentage of sales made through its direct sales teams. With surgical products driving the lion's share of group revenues and a clear growth trajectory, AMS is positioned for scalable growth, margin improvement, and long-term value creation.